James - Slack Capital (@Slack_Capital) header
James - Slack Capital (@Slack_Capital) profile picture

Uncovering asymmetric investment opportunities through deep analysis 𝘊𝘰𝘮𝘮𝘰𝘥𝘪𝘵𝘪𝘦𝘴 | 𝘋𝘦𝘦𝘱 𝘛𝘦𝘤𝘩 | 𝘉𝘪𝘰𝘵𝘦𝘤𝘩

Author 👉
Joined May 2021
Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)Photo by James - Slack Capital (@Slack_Capital)
James - Slack Capital retweeted
We're announcing our quarterly investor call on Thursday, November 19, 2026, at 5PM ET / 2PM PT to discuss @eXoZymes results for the third quarter 2026. A press release detailing these results will be issued prior to the call. Investors can pre-register for the call here: na2.hubs.ly/H08-y000 $EXOZ
2
8
168
International Business Times (@IBTimes) recently published an article exploring my investment thesis on @eXoZymes $EXOZ and the research I've been sharing through Slack Capital since early 2025! ibtimes.com/why-exozymes-sta… Since first discovering eXoZymes in January 2025, I've spent considerable time researching the company's cell-free biomanufacturing technology and its commercial potential. The more I've learned, the more convinced I've become that eXoZymes represents one of the most significant asymmetric investment opportunities I've ever encountered. The article highlights one of the central reasons behind my conviction... eXoZymes' potential to build a compounding value flywheel. @eXoZymes isn't simply developing another single molecule based on binary risk . The company is building a platform designed to repeatedly identify highly valuable molecules, develop the Exozyme systems required to manufacture them and bring these molecules to market. The potential is that each successful programme makes the next one easier to develop and commercialise. As eXoZymes builds its technical expertise, manufacturing capabilities and commercial partnerships, it could create a foundation for an expanding portfolio of valuable molecules. We're beginning to see encouraging progress with the company's leading NCT programme, which has already achieved significant manufacturing milestones and is now advancing towards commercial-scale production. While there is still plenty to prove, I believe the opportunity for eXoZymes to repeat this process across multiple molecules is what makes its long-term potential so compelling. You can read the International Business Times article here: ibtimes.com/why-exozymes-sta…
2
12
468
Interesting that @eXoZymes $EXOZ last two publications (Mashable & Benzinga) have both focused on the same narrative… AI is rapidly advancing our ability to design new molecules but actually manufacturing them remains a major bottleneck. These articles take time, money and coordination to publish, so I suspect Lasse has been quite intentional with the narrative eXoZymes is pushing into the market. It’s interesting looking at what they’re promoting and what eXoZymes has actually publicly demonstrated so far. We’ve seen evidence validating the platform’s ability to manufacture naturally occurring molecules including NCT, limonene, isobutanol and common/rare cannabinoids… however while eXoZymes has previously stated producing some new-to-nature analog compounds, we still haven’t seen any actual data demonstrating their broader capability to modify molecular structures and synthesise entirely new pharmaceutical compounds. That’s not to say that eXoZymes can’t already do it… But there’s obviously a difference between theoretically claiming your technology can achieve it and releasing data for investors/partners to actually assess those claims. IMO the recent articles are a bold narrative and could be part of a deliberate strategy to warm up the market ahead of an announcement… potentially from either our new-to-nature cannabinoid programme, NCT analogs or something else. Personally, I’d love to see something on cannabinoids as IMO this would generate significant market interest. $100s of millions have already been spent in this space, countless companies have attempted to develop novel cannabinoid compounds yet have failed and there’s a strong, cult-like following among cannabinoid investors. Announcing not only the successful synthesis of new-to-nature cannabinoid analogs along with strong lab testing results could garner significant market interest. I take Lasse to be a calculated strategist… so I doubt the recent article focus on AI-designed molecules and the manufacturing bottleneck is merely a coincidence
1
7
392
Recently relistened the @messaginglab and in conjunction with @eXoZymes new NCTx presentation, I realised I had NCT’s GRAS process all wrong… I thought we were pursuing an FDA GRAS Notification first but we're actually pursuing a Self-Affirmed GRAS Self-Affirmed GRAS is where a company prepares a comprehensive safety dossier for an independent expert panel to review. If/once affirmed, NCT can then be launched to market This dossier needs to include: - Safety Basis: As the NCTx presentation states, we already have a published 90-day toxicology study, which supports an estimated safe dose of 992 mg/day for a 70 kg adult - Human Trials: There are two existing published human studies on NCT/NFT which will support the safety assessment. We also have the planned single-dose human PK study in Q1, which could strengthen the dossier case - Manufacturing: Requires a clearly defined manufacturing process. We are currently undergoing the tech transfer process with Curia whether their determining the exact workflows, equipment, methods, quality controls etc. - Product Stability: Need to demonstrate that NCT remains stable during storage. I assume some of this work has already been complete - Dietary Exposure Assessment: Calculation of the estimated daily intake based on the intended dose. Again, seems simple enough so should be complete - Comprehensive Scientific Literature: Existing published research on NCT for which we know there are hundreds of papers So were essentially waiting on Curia to finalise the commercial manufacturing process and establish the relevant purity/quality specs… in addition to the while the human PK study which should provide further support One important distinction is that we don't necessarily need Curia to have completed full commercial-scale production before obtaining GRAS affirmation. We need sufficient manufacturing and analytical evidence to demonstrate that the final product is consistently produced and that its safety profile is adequately understood. This aligns to the presentation's stated timeline - Q4 2026: Curia tech transfer complwted - Q1 2027: Single-dose human PK study - Q2 2027: Self-Affirmed GRAS It's taken us quite some time to get to this stage… but I expect future compounds will progress much faster towards Self-Affirmed GRAS. As we know, eXoZymes has been building out its commercial playbook with NCT so we can utilise the knowledge, networks and relationships established to accelerate future compounds. I'm sure there will be synergies across the manufacturing processes used at Curia. Right now, we're undertaking our first commercial-scale tech transfer with Curia learning the ins and outs of not only NCT but also how our cell-free technology operates. While each compound will require its own process development, much of the learnings around enzyme production, manufacturing, purification and scale-up should be transferable… Additionally, we now have Oliver Loson onboard who could help design and coordinate human-use studies to strengthen future compounds dossiers and fill any gaps. We didn't have him onboard during NCT's early development so now having this capability internally from an earlier stage could help accelerate future programmes
1
9
179
James - Slack Capital retweeted
WTR’s Robert Sassoon on eXoZymes $EXOZ and how its cell-free platform delivered a 10-fold productivity gain in NCT manufacturing, plus the milestones to watch ahead of a 1H27 launch. Listen now, link in the replies.
1
3
6
393
Last week I released an article exploring @eXoZymes $EXOZ Genesis Mission project and what it could mean for the company’s broader development platform. If the digital twin can help @eXoZymes predict performance, narrow the design space and reach promising production conditions with fewer physical experiments, the impact could extend well beyond any single molecule. And this is where the company's compounding flywheel I keep referencing becomes so powerful! A faster development engine could allow @eXoZymes to develop and de-risk more compounds in parallel, while the data, knowledge and learnings from each program feed back into the platform and help improve the next. Full article: slack-capital.com/p/exozymes…
1
1
10
281
Imagine a future where developing a new high-value nutraceutical or pharmaceutical compound could start with the click of a button. Input the target compound and the system spits out: • The synthesis pathway • Which enzymes are required • How those enzymes should be optimised • Recommended reaction conditions • Expected yield and productivity • Potential manufacturing economics This is what I find so exciting about @eXoZymes $EXOZ Genesis Mission work. Combine the digital twin being developed with Lawrence Berkeley National Laboratory with @eXoZymes existing AI and pathway-design capabilities and you can start to see the bigger vision: A future where @eXoZymes can take a target compound, computationally design its path to production and rapidly validate the most promising process in the lab. Full article: slack-capital.com/p/exozymes…
1
10
370
One of the reasons @eXoZymes $EXOZ is so well suited to predictive modelling comes down to the nature of cell-free systems. Traditional biomanufacturing takes place inside a living cell. Production pathways operate alongside metabolism, growth, regulation and other biological processes that can influence the final cell-based synthesis result, even when they have little to do with producing the actual target compound itself. Because @eXoZymes is cell-free, much of that complexity is removed. Its reactions are built around defined enzymes, feedstocks, cofactors and operating conditions that can be directly controlled and measured, behaving more like chemistry than biology. That distinction could be incredibly important for the Genesis digital twin. The more clearly you can understand how changing a specific variable affects yield, conversion or productivity, the better the data available to train a model to predict how the process will behave under different conditions. Full article: slack-capital.com/p/exozymes…
2
12
451
Interesting comment from @heltzen on the @messaginglab podcast suggesting @eXoZymes may announce another product before year end! There’s not many months left in 2026… I'd assume it's one of the 5 compounds currently in rapid proof-of-concept… and I personally believe it will be something skincare related. The company rarely mentioned skincare compounds until recent and now it's come up a few times After the recent poor cap raise interest, I’d say @eXoZymes realised they needed more control over their own funding, essentially being bled dry before the cap raise money landed. They know investors want to see a commercial deal and IMO its still some time before NCT or Cannabinoid Analogs are licensed out. So my guess is the team expedited the development of a skincare compound as they’ve already created a commercial playbook via NCT A deal could bring an initial payment or some other form of funding which could reduce the need for another near-term cap raise. Remember, Heltzen has been directing family offices to buy on the open market rather than wait for a future capital raise If the potential of a near-term skincare deal holds true, eXoZymes has probably been in consultation with a cosmetic brand on which compound to develop. They may have agreed to skip upfront R&D payment given the development risk and a payment/licensing fee would follow once the compound is developed Of course, these is purely speculation on my part… but I have confidence in management reducing shareholder dilution by opening the door to smaller/faster compound opportunities that bring in some funding Even a payment of $5-8m would provide roughly 9 months of runway at recent operating burn. More than enough to get us to analog deals!
1
6
268
James - Slack Capital retweeted
Update from @Slack_Capital: What if @eXoZymes’ biggest opportunity isn’t a single molecule, but an AI-powered engine that combines computational design with cell-free biomanufacturing to repeatedly turn previously inaccessible chemistry into new products - and then do it all over again? Read the full update from Slack Capital here: na2.hubs.ly/H08fgX20 $EXOZ
1
2
10
357
What excites me most about @eXoZymes $EXOZ Genesis Mission project is where this work could ultimately lead to. slack-capital.com/p/exozymes… Working with Lawrence Berkeley National Laboratory, @eXoZymes is developing an AI-powered digital twin to predict how its cell-free enzymatic pathways perform under different operating conditions. Combining this model with @eXoZymes existing pathway design, enzyme selection and AI-driven enzyme optimisation capabilities, and a much more powerful development engine starts to emerge. Over time, @eXoZymes could computationally design much of the production process upfront, resulting in faster development timelines, fewer experimental cycles, lower costs and significantly more compounds progressing through the platform in parallel. All of which feeds directly back into the compounding flywheel I’ve continually referenced. exozymes.com/blog/genesis-mi…
1
1
9
589
I received the following comment from @PatentVest’s Chief IP Officer, Will Rosellini, on my LinkedIn post. PatentVest currently provides intellectual property services to @eXoZymes, supporting the development and protection of its IP portfolio. The digital twin is the part worth watching, and for a reason the post hints at but does not say. A model that predicts how a cell-free pathway performs under different conditions is only as good as the gap between what it predicted and what the reactor did. That gap is data no competitor can buy, scrape or license. It exists only at the bench that runs the pathway. In language AI the moat was a corpus. In biomanufacturing the moat is the prediction error coming off your own equipment, and eXoZymes is one of the few companies positioned to generate it on purpose. That changes the IP question. The molecules and the enzymatic routes are patent territory: observable in the product, enforceable at the border. The twin, the enzyme variants it selects and the error data that trains it are trade-secret territory. A patent on that layer would publish the recipe and hand a competitor with a reactor the starting point for the same loop. The companies that win this category will be the ones that draw that line early and write it into every scale-up and partner agreement, so the data generated at a partner's plant belongs to the model, not the plant.
4
84
What an interview! It just clicked what @eXoZymes $EXOZ is cooking here… eXoZymes is going to remain laser-focused on the Nutra and Pharma space. This market is enormous and the opportunity alone represents a monumental investment case. At the same time, eXoZymes recognises that its cell-free technology has obviously applications far beyond Nutra and Pharma. It could support cleaner biomanufacturing, enable new advanced chemicals and materials, and ultimately usher in a new industrial era. However, as Michael has continually stated, the challenge is having disciplined focus. eXoZymes can't realistically build and commercialise products across every industry. So for industries outside Nutra and Pharma, eXoZymes plans to license its core cell-free technology to companies that already specialise in those markets. Take biofuels for example. Rather than eXoZymes trying to build an entire biofuels business from scratch, it could license its cell-free technology to a company such as LanzaTech. This company already has the infrastructure, expertise, customers and commercial networks to bring products to market. By licensing eXoZymes’ technology, companies could gain access to the significant advantages of cell-free manufacturing over their existing cell-based systems, without having to spend years developing a cell-free technology themselves. In return, eXoZymes could receive a licensing fee or royalty for the use of its platform. This also explains why eXoZymes is on the leadership committee of BioMADE, helping guide the broader development of the United States cell-free manufacturing industry. This strategy is also supported by initiatives such as the Santalene grant, where eXoZymes technology has been provided to universities to help advance the field. Having personally connected with eXoZymes management team over the past two years, it's clear there is a genuine desire to advance cell-free technologies to the broader market and help usher in a more prosperous and sustainable industrial future. Of course, capturing licensing agreements along the way certainly doesn’t hurt. As eXoZymes has been open about, more biotech companies will eventually enter the cell-free space as the advantages are so obvious! But for a large organisation such as LanzaTech, the choice could be simple... spend multiple years and significant capital trying to develop its own cell-free platform or pay a licensing fee and gain access to proven technology immediately. I know what I would choose. This strategy will likely take years to fully unfold. But if it works as intended, eXoZymes would not need to dominate every individual industry itself. It could provide the underlying technology that helps power them #poweredbyexozymes eXoZymes could become the backbone of a new industrial era 🤯
CEO of @eXoZymes, Michael @heltzen, joins @messaginglab's 'Grow Everything' podcast to explain how cell-free biomanufacturing is opening new possibilities for natural products, nutraceuticals, and medicines. “The only thing that will really, really stop that conversation about ‘can cell-free biomanufacturing really be true?’ is when people can pick a product off the shelf at their pharmacy and buy it for themselves. At that point, I think the conversation will finally - even for the most conservative segments - be over, that this is a new way of doing biomanufacturing without cells. It enables products that otherwise would be impossible or very difficult.” Catch the entire episode right here: na2.hubs.ly/H0895ZS0 $EXOZ
2
1
1
12
2,000
Great to see Water Tower initiate coverage of @exozymes $EXOZ as the story moves from science toward commercial execution. Definitely worth a read! • NCT commercialisation • Curia scale-up • 100x+ manufacturing cost improvement • Cannabinoid pipeline • AI + enzyme design • Asset-light model
WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity @WTR_Research’s new research report takes a close look at how @eXoZymes is moving from a promising scientific platform toward a potentially scalable commercial business. 7 things to know from the report: * eXoZymes is moving from scientific validation toward commercial validation. * NCT has emerged as the company’s key near-term commercial opportunity. * The company has made significant progress in improving the economics of NCT production. * Curia Global is now helping take the technology beyond pilot-scale production. * The report sees substantial longer-term potential in pharmaceutical applications of the platform. * Cannabinoids, santalene and five new molecules add further pipeline optionality. * The next major milestones are scale-up, commercial partnerships and turning technical progress into revenue. For investors looking to understand what has changed at $EXOZ, where the company is heading, and what needs to happen next, the report provides a timely look at the company’s evolving strategy and commercial opportunity. Read the full report here - available with free login! na2.hubs.ly/H088rNs0
2
10
385
James - Slack Capital retweeted
eXoZymes Selects @CuriaCDMO as Commercial-Scale Manufacturing Partner for NCT Paul Opgenorth, PhD, VP of Development and co-founder of @eXoZymes, elaborates “We have demonstrated the NCT process at pilot scale and substantially improved its productivity and economics. Transferring our entire integrated process - from enzyme production through the cell-free NCT reaction to product purification - into a commercial manufacturing environment represents an important validation of its maturity. Having visited Curia’s facilities in both Spain and Italy, I’m confident we have selected a partner with the technical capabilities and infrastructure to take this next step with us.” Read the full press release here: na2.hubs.ly/H07Gv5Q0 $EXOZ
1
2
1
13
1,857
James - Slack Capital retweeted
This is a really great research report. Definitely give it a read! @Slack_Capital
1
5
174
In this article, I break down why @eXoZymes’ strategic shift will drive transformative upside for $EXOZ By independently advancing and de-risking assets like NCT before partnering, they maximise downstream leverage and create a self-reinforcing flywheel of $EXOZ value creation
Slack Capital: Inside EXOZ’ strategic shift - building a compounding value flywheel How @eXoZymes’ new strategy of retaining, de-risking and monetising high-value assets could create a self-reinforcing flywheel of value creation The full research report from @Slack_Capital is freely available here: na2.hubs.ly/H07t8HP0 $EXOZ
1
8
1,202
James - Slack Capital retweeted
Research coverage from @WTR_Research: $EXOZ 2Q26 update - from platform validation to commercial execution - The productivity result is the standout headline, beating management’s own hurdle. - Scale-up and reproducibility have already been demonstrated independently - The business model is becoming increasingly asset-light - The strategy reset should strengthen the negotiating position of @eXoZymes Read the full update here - accessible with a free login: na2.hubs.ly/H07pTT40
6
16
574